NCT07138560 - BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

May 15, 2026

Study Completion Date

May 15, 2027

Conditions

Parkinson Disease

Interventions

DRUG

CREXONT ER

exploring shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods

Trial Locations (1)

44195

RECRUITING

Cleveland Clinic, Cleveland